[go: up one dir, main page]

AU2002214305A1 - Pharmaceutical preparation containing copolyvidone - Google Patents

Pharmaceutical preparation containing copolyvidone

Info

Publication number
AU2002214305A1
AU2002214305A1 AU2002214305A AU1430502A AU2002214305A1 AU 2002214305 A1 AU2002214305 A1 AU 2002214305A1 AU 2002214305 A AU2002214305 A AU 2002214305A AU 1430502 A AU1430502 A AU 1430502A AU 2002214305 A1 AU2002214305 A1 AU 2002214305A1
Authority
AU
Australia
Prior art keywords
pharmaceutical preparation
preparation containing
copolyvidone
drug
containing copolyvidone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002214305A
Inventor
Makoto Fukuta
Hajime Ishida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2002214305A1 publication Critical patent/AU2002214305A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A stabilized preparation which comprises: a drug and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated. The drug is chosen among those drugs which are unstable in the presence of polyethylene glycol.
AU2002214305A 2000-11-17 2001-11-16 Pharmaceutical preparation containing copolyvidone Abandoned AU2002214305A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000351223 2000-11-17
JP2000-351223 2000-11-17
PCT/JP2001/010016 WO2002040054A1 (en) 2000-11-17 2001-11-16 Pharmaceutical preparation containing copolyvidone

Publications (1)

Publication Number Publication Date
AU2002214305A1 true AU2002214305A1 (en) 2002-05-27

Family

ID=18824316

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002214305A Abandoned AU2002214305A1 (en) 2000-11-17 2001-11-16 Pharmaceutical preparation containing copolyvidone

Country Status (7)

Country Link
US (3) US20040018239A1 (en)
EP (2) EP2305219A1 (en)
AT (1) ATE469644T1 (en)
AU (1) AU2002214305A1 (en)
CA (2) CA2650698C (en)
DE (1) DE60142305D1 (en)
WO (1) WO2002040054A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
JP2004339162A (en) * 2003-05-16 2004-12-02 Shin Etsu Chem Co Ltd Pharmaceutical solid preparation containing poorly soluble drug and method for producing the same
AR045062A1 (en) * 2003-07-18 2005-10-12 Santarus Inc PHARMACEUTICAL FORMULATIONS TO INHIBIT THE SECRETION OF ACID AND METHODS TO PREPARE AND USE THEM
JP2006528182A (en) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド Pharmaceutical preparations and treatment of digestive diseases caused by acids
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
AU2005213472A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
WO2005117870A2 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8226977B2 (en) * 2004-06-04 2012-07-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
EP1760071A4 (en) * 2004-06-23 2008-03-05 Ono Pharmaceutical Co Compound having s1p receptor binding potency and use thereof
TWI400220B (en) * 2004-09-13 2013-07-01 Takeda Pharmaceutical Method for preparing photoactive amine derivatives
KR20080027783A (en) 2005-06-22 2008-03-28 다케다 야쿠힌 고교 가부시키가이샤 Tablets containing poorly soluble active ingredients
AR061478A1 (en) 2006-06-19 2008-08-27 Takeda Pharmaceutical TRICYCLE COMPOUND AND PHARMACEUTICAL COMPOSITION
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CN104546746A (en) * 2013-10-28 2015-04-29 南京长澳医药科技有限公司 Ramelteon tablets and preparation process thereof
US10931859B2 (en) 2016-05-23 2021-02-23 InSyte Systems Light emitter and sensors for detecting biologic characteristics
US10713458B2 (en) 2016-05-23 2020-07-14 InSyte Systems Integrated light emitting display and sensors for detecting biologic characteristics

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617328A1 (en) * 1966-07-28 1971-06-03 Knecht Adolf O Dr New, sugar-free coatings for tablets and dragee cores
JPS456558B1 (en) * 1966-12-21 1970-03-05
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
HUT54035A (en) * 1989-06-22 1991-01-28 Chinoin Gyogyszer Es Vegyeszet Process for coating labile pharmaceutical active components for protecting from oxygen and humidity
DE3928183A1 (en) * 1989-08-25 1991-02-28 Goedecke Ag LACTAM-FREE CYCLIC AMINO ACIDS
US5401562A (en) * 1992-03-27 1995-03-28 Fuji Photo Film Co., Ltd. Paper material for photosensitive materials and method of producing the same
FR2698560B1 (en) * 1992-11-30 1995-02-03 Virbac Laboratoires Stabilized powdery active ingredients, compositions containing them, process for obtaining them and their applications.
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
EP0885210B2 (en) * 1996-03-08 2008-06-18 Takeda Pharmaceutical Company Limited Tricylic compounds having binding affinity for melatonin receptors, their production and use
HU225960B1 (en) * 1997-02-27 2008-01-28 Takeda Pharmaceutical Amine compounds, their production and use
US6248259B1 (en) * 1997-04-28 2001-06-19 Nitto Denko Corporation Optically active monomer, liquid crystal polymer, and optical element
ES2203963T3 (en) * 1997-05-30 2004-04-16 Osmotica Corp. MULTI-PATH OSMOTIC DEVICE.
KR100669280B1 (en) * 1998-05-15 2007-01-17 워너-램버트 캄파니 엘엘씨 Solid phase composition comprising gamma-aminobutyric acid derivative and preparation method thereof
AU4060599A (en) * 1998-06-09 1999-12-30 Takeda Chemical Industries Ltd. Pharmaceutical composition for treating or preventing sleep disorders
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
DE19961897A1 (en) * 1999-12-20 2001-06-28 Basf Ag Use of a film coating as a taste masking coating of pharmaceutical dosage forms
US6248359B1 (en) * 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent

Also Published As

Publication number Publication date
EP2305219A1 (en) 2011-04-06
US20170020841A1 (en) 2017-01-26
EP1334732A4 (en) 2006-03-15
CA2650698C (en) 2013-05-28
DE60142305D1 (en) 2010-07-15
US20040018239A1 (en) 2004-01-29
US10098866B2 (en) 2018-10-16
CA2428817A1 (en) 2002-05-23
CA2428817C (en) 2010-06-01
CA2650698A1 (en) 2002-05-23
WO2002040054A1 (en) 2002-05-23
EP1334732B1 (en) 2010-06-02
ATE469644T1 (en) 2010-06-15
US20090274733A1 (en) 2009-11-05
EP1334732A1 (en) 2003-08-13

Similar Documents

Publication Publication Date Title
AU2002214305A1 (en) Pharmaceutical preparation containing copolyvidone
AU2002216701A1 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
AU2001232337A1 (en) Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance
CA2311450A1 (en) Pharmaceutical aerosol compositions
AU1535799A (en) Pharmaceutical hydrogel formulations, drug delivery devices and methods
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
AR029333A1 (en) COMBINATION OF NON-INTERACTIVE DRUGS, PHARMACEUTICAL FORMULATION AND PHARMACEUTICAL PACKAGE INCLUDING SUCH COMBINATION AND THE USE OF AN INHIBITOR OF THE REDUCED HMGCOA IN THE PREPARATION OF A MEDICINAL PRODUCT USED IN COMBINED THERAPY
AU2002309172A1 (en) Pharmaceutical compositions containing polymer and drug assemblies
WO2002072034A3 (en) Chronotherapeutic dosage forms
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
NO20022998L (en) Pharmaceutical preparations which provide increased concentration of drug
AU5241199A (en) Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
AU1992595A (en) Hydrophobic drug delivery systems
EP0817655A4 (en) Intrapulmonary delivery of hematopoietic drug
AU2002333373A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
WO2001041742A3 (en) Antiviral medication
ATE383868T1 (en) PHARMACEUTICAL FORMULATION CONTAINING MEGALATRAN AND ITS PROPHARMACEUTICALS
AU2001278772A1 (en) Benzoic acid derivatives and drugs containing the same as the active ingredient
EP1044681A3 (en) Sustained release carbamazepine formulation
AU7594900A (en) Pharmaceutical formulations containing poorly soluble drug substances
AU4519399A (en) Anti-inflammatory pharmaceutical formulations
AU1650401A (en) Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
WO2002028424A3 (en) Kyberdrug as autovaccines with immune-regulating effects
WO2001082868A3 (en) A medicinal aerosol formulation
WO2002041829A3 (en) Oral nanosphere delivery